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Abstract
Primary Hyperparathyroidism (PHPT) is a common endocrine disorder,
which is seen at all ages, but primarily in post-menopausal women. While
commonly

asymptomatic,

clinical

manifestations

include

kidney

stones,

osteoporosis, and other symptoms. Parathyroid adenomas are the most common
cause of PHPT (85%), followed by hyperplasia (15%) and carcinomas (~1%).
Established genes associated with sporadic parathyroid adenomas include:
proto-oncogene cyclin D1 (PRAD1, CCND1), tumor suppressor gene MEN1, and
several cyclin-dependent kinase inhibitor genes CDKN2B, CDKN2C, CDKN1A,
and CDKN1B. Recently, compelling genetic evidence implicated that the ZFX
gene, part of the Kruppel C2H2 type zinc finger protein family, is a likely
parathyroid adenoma oncogene. It was found to be involved in almost 5% of all
cases (Soong & Arnold, 2014).
Genetic analysis is essential to this study, and the quality of the DNA used
is crucial in further analyses. Formalin-Fixation and Paraffin-Embedding (FFPE)
is commonly practiced preservation method, which unfortunately sacrifices the
quality of the DNA obtained from each sample. This is why it is imperative to
optimize a protocol that yields the most DNA, without introducing further
degradation. We tested multiple protocol modifications and determined that the
modified Qiagen Kit protocol, using Qiagen deparaffinization solution, with one-
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hour proteinase K incubation yielded optimal DNA concentrations and the least
amount of protein degradation.
With the discovery of ZFX as a candidate parathyroid oncogene, the
potential involvement of the highly homologous gene, ZFY, came to light. Since
analogous mutations in ZFY could have similar tumorigenic effects as those in
ZFX, we analyzed the entire coding region of ZFY in sporadic parathyroid
adenomas from male patients. This region was PCR-amplified and Sanger
sequenced in 117 adenomas. One novel variant c.1402C>T was found, resulting
in a predicted histidine to tyrosine change at position 468 of the ZFY protein. This
variant may have a role in the molecular pathogenesis of sporadic parathyroid
adenomas. Grasping the full understanding of the biology of ZFX and ZFY’s
mutations in the context of parathyroid tissue will further illuminate the
pathogenesis of parathyroid neoplasms.
In addition to involvement in sporadic parathyroid adenomas, recent
studies have also suggested that germline mutation in several CDKIs can cause
sydromic HPT (Pellegata et al 2006), with phenotypic presentation similar to
multiple endocrine neoplasia type 1 (MEN1). A patient diagnosed with
prolactinoma and familial hyperparathyroidism was referred for mutational
analysis of CDKIs p15, p18, p21, and p27. Mutational analysis of four CDKI
genes identified one novel variant, c.34G>A, in CDKN2C, encoding p18. We
believe this variant may contribute to the molecular pathogenesis of the patient’s
familial hyperparathyroidism and prolactinoma.
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In order to understand hyperproliferation and parathyroid neoplasia, an
inclusive study to optimize methodology for DNA extraction from FFPE samples
and, mutational analysis of ZFY, ZFX, and CDKIs was performed. The overall
findings of this project may suggest that ZFY or CDKIs mutations contribute to
the

development

of

x

hyperparathyroidism.

I. Calcium Homeostasis
Calcium is essential to most mammalian cellular functions. Serum calcium
levels are maintained by the parathyroid gland, which is the master regulator of
calcium homeostasis, through regulated secretion of parathyroid hormone (PTH).
Under normal physiological conditions, subtle decreases in blood calcium levels
stimulate the secretion of PTH, which in turn stimulates the increase of serum
calcium through effects on the gastrointestinal, renal, and skeletal systems. This
stimulation increases calcium absorption, as well as the mobilization of
mineralized calcium in the bone, and decreases calcium excretion. The resulting
elevation in serum calcium levels feed back on the parathyroid glands to
decrease PTH secretion (Figure 1).
Primary hyperparathyroidism (PHPT) is a common endocrine disorder,
with its highest incidence in post-menopausal females (Marcocci and Cetani
2011). Patients with primary hyperparathyroidism exhibit hypercalcemia with an
unsuppressed parathyroid hormone level. While primary hyperparathyroidism is
generally asymptomatic in the western world, marked hypercalcemia can lead to
gastrointestinal symptoms, bone problems such as osteoporosis and osteitis
fibrosa cystica, effects on the central nervous system, and kidney stones.
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Figure 1. Calcium Homeostasis
The parathyroid glands function to produce PTH in response to low serum
calcium. PTH acts on the kidneys, bones and intestines. All three target
organs work together to increase serum calcium levels, which then feedback
on the parathyroid glands, shutting down PTH production. In primary
hyperparathyroidism, this feedback loop is lost, and this leads to uncontrolled
PTH secretion and elevated calcium levels.

II. Basic Tumor Biology
A. Tumorigenesis
Tumors are caused by genetic mutations triggering uncontrolled
cell proliferation. Gene mutations are typically categorized as either somatic or
germline mutations. Somatic mutations can occur in any of the cells of the body
except the germ cells (sperm and egg) and therefore are not passed on to
children (Rati, 2011). In contrast, germline mutations can be passed on to some
or all progeny. Somatic mutations can be represented in a sector of identical cells
from a single progenitor cell or phenotypically represented as a dominant
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mutation that typically occurs after the organism has fully developed (Li, 2004).
Mutations that occur in germline tissue happen at fertilization or during the
process of development in sex cells. Familial syndromes stem from germline
mutations that are transmitted to offspring and are present in every cell. When a
mutation gives a selective advantage to a cell, leading to a clonal outgrowth, it is
considered a driver mutation. Alternatively, passenger mutations have no effect
on the fitness of a cell but may be associated with a clonal expansion. Neoplasia
or abnormal cell growth may be malignant or benign. Malignant tumors are
invasive with rapid growth, while benign adenomas are slow growing noninvasive tumors that do not metastasize.
B. Clonality
The term clonality is related to understanding the cell of origin giving rise
to daughter cells. Monoclonality refers to daughter cells arising from a single cell,
while polyclonality refers to cells proliferating from multiple progenitor cells.
Clonality can be assessed with molecular analysis. In female patients, tumor
clonality can be evaluated with X chromosome inactivation assays, based on the
concept that in every female cell, one X chromosome becomes inactivated and
the pattern of which chromosome becomes inactivated is random (Brown CJ et al
2000).
C. Tumor Genes
Mutations in tumor suppressor genes play a role in the pathogenesis of
cancer, whether it is complete or partial tumor suppressor inactivation (Berger et
al 2011). Oncogenes are activated by mutation, gene amplification, or
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chromosome rearrangements that contribute to the development of a neoplastic
phenotype. There are two classes of oncogenes one lowers the requirements for
growth factors leading to a change in the cells phenotype, while the other class
saves cells from apoptosis.

III. Hyperparathyroidism
Hyperparathyroidism is a biochemical diagnosis in which excessive
secretion of PTH leads to high blood calcium. Discerning if a patient should be
diagnosed with primary or secondary hyperparathyroidism relies on the
biochemical differences of high and low calcium levels, respectively. There are
two forms of primary hyperparathyroidism, sporadic and familial.
A. Familial Hyperparathyroidism
Familial hyperparathyroidism can be diagnosed based on a family history
of PHPT or other features suggestive of a familial multiple endocrine neoplasia
syndrome. Inherited (familial) syndromes account for ~5% of Primary
Hyperparathyroidism (PHPT) (Pepe J et al 2011).
The multiple endocrine neoplasia term is based on two or more endocrine
glands producing tumors. Depending on the pattern of the benign or malignant
tumors, it is characterized as one of the several distinct syndromes, which are
summarized in Table 1. MEN1 is characterized by tumors in the endocrine
pancreas, pituitary, and most commonly in the parathyroid. This syndrome is
caused by mutations in the MEN1 gene (70-95%) of cases or cyclin dependent
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kinase inhibitor genes (CDKIs) p15 (1%), p18 (0.5%), p21 (0.5%), p27 (1.5%)
(Marini F 2008).
MEN2 is caused by mutations in the RET gene and is further divided into
two different subtypes: MEN2A and MEN2B. MEN2A causes medullary thyroid
cancer, pheochromocytoma, and adenomas in the parathyroid. MEN2B causes
medullary

thyroid

cancer,

marfanoid

habitus/

mucosal

neuroma,

and

pheochromacytoma. MEN4 shares the same phenotypic presentation as MEN1,
however MEN4 is caused by mutations in the CDKN1B (p27) gene (Table 1).

Table 1. Multiple Endocrine Neoplasia Syndromes
Syndrome
MEN1

Gene
MEN1

MEN2A

RET

MEN2B

RET

MEN4 (MENX)

CDKN1B

Manifestations
Pituitary Adenoma,
Parathyroid Neoplasia,
and Pancreatic Tumors
Parathyroid Neoplasia,
Medullary Thyroid
Carcinoma, and
Pheochromacytoma
Mucosal Neuromas
Marfanoid Habitus,
Medullary Thyroid
Carcinoma, and
Pheochromacytoma
Pituitary Adenoma
Parathyroid Neoplasia,
and Pancreatic Tumors

B. Sporadic Hyperparathyroidism
There are three ways for sporadic, primary hyperparathyroidism to
manifest: parathyroid adenomas are most common (85%), parathyroid
hyperplasia is less common (15%), and rarely, parathyroid carcinoma can occur
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(<1%) (Loya SolIs 2014). There are a few established tumor genes including
cyclin D1 (CCND1/PRAD1) and multiple endocrine neoplasia type 1 (MEN1)
(Costa-Guda,,2014). Candidate oncogenes include

β-Catenin (CTNNB1),

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 subunit (EZH2), and Zinc
Finger Protein X-linked (ZFX) (Duan K 2015). The frequencies of various gene
mutations identified in sporadic parathyroid adenoma are illustrated in Figure 2.

Figure 2. Genetic Abnormalities in Sporadic Parathyroid Adenomas
MEN1 is the most frequently mutated gene in sporadic parathyroid adenomas.
Rearrangements of cyclin D1 and intragenic point mutations of CDKI genes have
also been identified as genetic drivers. Rarely, mutations occur in other genes,
such as β-Catenin (CTNNB1) and EZH2.

CCND1/PRAD1, which encodes cyclin D1, was first identified as a human
oncogene based on its involvement in parathyroid tumors (Motokura T., Arnold,
1991). Overexpression of cyclin D1 is seen up to 40% of sporadic parathyroid
tumors. Cyclin D1 gene rearrangements seen in up to 8% of tumors directly
causes this overexpression. Cyclin D1 gene rearrangement is a pericentromeric
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inversion of chromosome 11 that is well characterized, which places the 5' PTH
regulatory region upstream of the cyclin D1 gene, as shown in Figure 3.

Figure 3. CCND1/PRAD1 gene rearrangement
A schematic of the pericentromeric inversion of chromosome 11. This
rearrangement places the 5' PTH regulatory region upstream of the cyclin D1
gene.

Cyclin D1 is a regulator of the subunits CDK4 and CDK6

these

complexes are critical for the progression of the cell cycle, specifically during the
G1 phase (Figure 4). Cyclin dependent kinases (CDKs) and cyclins bind together
to promote the continuation of the cell cycle, while cyclin dependent kinase
inhibitors (CDKIs) are put in place to counteract cell proliferation. In the early G1
phase, cyclin dependent kinase 4 and 6 are associated with cyclin D. Later in the
G1 phase, after the restriction point, CDK2/ cyclin E complex stimulates the
transition of the cell cycle from G1 to S phase, which determines cell division.
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The combined CDK 2/ cyclin A complex governs the S phase entry, initiating
DNA replication. The cell is then committed to proliferate with the cyclin B and
CDK1 complexes activating mitosis.
Mutations in several CDKI genes, including p27, have recently been
identified as important contributors to a subset of parathyroid adenomas.
Mutations have been identified in a few additional candidate genes, but, to date,
their ability to drive parathyroid tumorigenesis experimentally has not been
demonstrated. Mutations in β-catenin and EZH2 appear very rarely in parathyroid
adenomas. In contrast, mutations in ZFX appear to be more common.
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Adapted from Donavan J. et. Al. 2000

Figure 4. Cell Cycle Control
The cell cycle displays the four phases; cell growth (G1), DNA synthesis (S), cell
growth (G2), and mitosis (M). Progression through the cell cycle is governed by
interactions between Cyclins, CDKs and CDKIs
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Aims and Objectives
The overall aim of this dissertation was to further the understanding of genetic
events that lead to parathyroid hyperproliferation and neoplasia. This was done
through the following specific aims:
1. To optimize a protocol for DNA extraction from formalin fixed paraffin
embedded tissue.
An optimized protocol for DNA extraction from formalin fixed paraffin embedded
(FFPE) tissue is essential for further analysis of genetic events promoting
parathyroid neoplasia. To this end, we tested several different protocol
modifications that produce the highest DNA yields while minimizing degradation.
2. To determine the role of ZFY in sporadic parathyroid adenomas.
Recurrent, somatic mutations in the ZFX gene have recently been identified in
parathyroid adenomas. Since ZFX and another gene, ZFY, are virtually identical,
we hypothesized that parathyroid adenomas may contain mutations in the ZFY
gene, similar to those observed in ZFX. To test our hypothesis, we directly
analyzed the entire coding region of ZFY in parathyroid adenomas from male
patients.
3. To perform CDKI mutational analysis in a patient with unexplained MEN1.
A

patient

with

phenotypic

MEN1

(prolactinoma

and

familial

hyperparathyroidism), but negative for MEN1 gene mutation was referred to us
for Cyclin Dependent Kinase Inhibitor gene sequencing, in order to bring clarity
for genetic counseling.

10

Chapter 1. Optimization of a Protocol for DNA Extraction from Formalin
Fixed Paraffin Embedded Tissue
Introduction
Tissues are commonly fixed in formalin and embedded in paraffin for
histopathological diagnosis and preservation after biopsies or surgeries. Formalin
fixation and paraffin embedding is invaluable for the purpose of preserving tissue
for long-term storage and later pathological studies. Fixation is one of the most
vital steps in the preservation process. As illustrated in Figure 5, formalin crosslinks amino acids in proteins and nitrogen molecules in nucleic acids to prevent
tissue decay by autolysis or putrefaction. Unfortunately, in comparison to
preservation by quickly freezing tissue, the formalin fixation process decreases
the quality of the nucleic acids that can be extracted from the tissue. Therefore,
optimizing a protocol for DNA extraction from formalin-fixed, paraffin-embedded
(FFPE) tissue is crucial for gaining higher DNA yields without increasing
degradation.
Extraction of DNA from FFPE tissues requires removal of the paraffin wax
(deparaffinization), cell lysis releases proteins and nucleic acids, proteinase K
digestion to remove contaminating proteins and inhibit nuclease activity, and
purification through a DNA-binding column or other methods. To develop an
optimized protocol for DNA extraction from FFPE tissue, we tested two different
deparaffinization methods, modifications to the proteinase K digestion time and
elution protocol, using column-based DNA purification.
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Adapted from Qiagen QIAMP DNA FFPE Tissue Handbook 2012

Figure 5. Formalin Fixation Effects
Crosslinking between proteins and nucleic acids are caused by formalin fixation.
This figure represents how prolonged fixation induces crosslinking.

Materials and Methods
Deparaffinization
Extracting DNA from paraffin blocks begins with slicing tissue with a
microtome into sections of 20 μM. The deparaffinization procedure in this
experiment

used

two

different

methods:

Deparaffinization Solution (Qiagen).
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either

xylene-ethanol

or

Deparaffinization with xylene-ethanol is done under the hood to minimize
exposure to hazardous fumes. The tissue section is soaked in 1 mL of xylene for
10 minutes, and then centrifuged for 30 seconds. This step is followed by
saturating the tissue in 1 mL of 100% ethanol for 10 minutes and centrifuged
again for 30 seconds. This process of xylene and ethanol is repeated in a second
cycle. After the cycles are completed, the sample must be dried at room
temperature. Tested modifications to the xylene-ethanol deparaffinization
protocol include preheating xylene to 65°C, chilling the ethanol to 4°C, and
increasing the number of cycles.
Deparaffinization with Qiagen Deparaffinization Solution is done by incubating
the tissue section with 320 μL of Deparaffinization Solution at 56°C for either
three or eight minutes.
Proteinase K Digestion
Following deparaffinization, the tissue was incubated with proteinase K
in the presence of ATL lysis buffer. Incubations were done for either one hour, 90
minutes, or overnight.
Column Purification
DNA was purified using the QIAamp DNA FFPE Kit, following the
manufacturer-recommended protocol. Modifications tested included using chilled
ethanol or increasing the incubation time with the AE elution buffer from 5 to 10
minutes. A summary of all protocol modifications is shown in Table 2.
Analysis of DNA Quality and Yield
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The amount of DNA degradation was analyzed using gel electrophoresis
and imaging. DNA quality and yield were further analyzed using a Nanodrop
2000c and Qubit fluorometer. The Nanodrop is used to quantify DNA via
spectrophotometry. Nucleic

acids

absorb

light

at

a

wavelength

of

260 nm, the 260/280 and 260/230 ratios measure different characteristics.
The 260/280-ratio measures purity of DNA and RNA; the optimal range for DNA
is 1.7-2.0 ratios above 2 suggest the presence of RNA, while a ratio lower than
1.7 suggest contamination with phenol, protein, or EDTA. The 260/230 ratio
represents pure DNA at a score that ranges from 2.0-2.2. A score that is lower
than this range may reveal contamination of carbohydrates, phenol, or EDTA.
The Qubit fluorometer can quantify DNA, RNA, and protein using different
fluorescent dyes. Each dye is specific for one type of molecule: DNA, RNA or
protein. The Qubit is generally more precise in determining the DNA
concentration but cannot simultaneously give information about RNA or protein
contamination.
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Table 2. Formalin Fixed Paraffin Protocol Embedded Protocol
Protocol

Qiagen

Deparaffinization
Original

Incubate at 56°C-3 min,
Cool at (15-25°C)

1 ml 100% EtOH 10 min (2x’s)
Centrifuge at Max 1 min
1 mL 100% EtOH 10 min (2X’s)
Dry at room temperature

Deparaffinization Method
Modified

Incubate at 56°C-8 min
Cool at (15-25°C)

Preheat: Xylenes 65°C
Chill: Ethanol 4°C
1 mL 100% EtOH 10 min (5X’s)
Dry at room temperature

Proteinase K Incubation
Original

1 Hour

1 Hour

1 Hour
90 Minutes
Overnight

1 Hour
90 Minutes
Overnight

Proteinase K Incubation
Modified

Xylene-Ethanol

Column Purification
Original

Add AL Buffer 200L  Add EtOH 200 μL
Centrifuge QI amp Column AW1 500 μL
 AW2 500 μL  25 μL AE Buffer 5 min

Column Purification
Modified

Add AL Buffer 200 μL > Add chilled EtOH 200 μL
Centrifuge QI amp Column  AW1 500 μL
 AW2 500 μL  25 μL at AE Buffer -10 min

Results
Five

different

protocols,

include

two

distinct

approaches

of

deparaffinization were tested. The first comparison explored the two different
deparaffinization methods, using an overnight proteinase K digestion and the
manufacturer-recommended QIAamp DNA FFPE Kit (“original”) protocol (Figure
6). The xylene-ethanol method (designated A) demonstrated consistently high
levels of DNA degradation across all four tumors. In comparison, the Qiagen
Deparaffinization method (designated B) showed less degradation. However, the
xylene-ethanol method gave higher DNA yields.
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/

B
A
Figure
A Proteinase K Incubation
A 6. Original Protocol with Overnight
A. Lower levels of DNA degradation were noted with the xylene-ethanol method
as compared to the Qiagen method when using the original protocol with
overnight proteinase K digestion.
B. The xylene-ethanol method also produced greater DNA yield.

The second comparison explored the two different deparaffinization
methods, using a shorter, one-hour, proteinase K digestion and the
manufacturer-recommended QIAamp DNA FFPE Kit (“original”) protocol (Figure
7). In this experiment, the Qiagen Deparaffinization method consistently showed
less degradation across samples and much higher (up to 3x) DNA yields.
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A
B
Figure
A 7. Original Protocol with One Hour
A Proteinase K Incubation

A. Lower levels of DNA degradation were noted with the Qiagen method as
compared to the xylene-ethanol method when using the original protocol with 1hour proteinase k digestion.
B. The Qiagen method also produced greater DNA yield.

The third comparison explored the two different deparaffinization methods,
using a one-hour proteinase K digestion but with modifications to the
manufacturer-recommended QIAamp DNA FFPE Kit (“modified”) protocol (Figure
8). The modifications included using chilled ethanol and increased incubation
time with the elution buffer. For the xylene-ethanol method, the number of cycles
was also increased from two to five cycles. In this experiment, the Qiagen
deparaffinization method demonstrated significantly lower degradation with
higher DNA yields.
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A
B
Figure
A 8. Modified Protocol with One Hour Proteinase K Incubation

A. Lower levels of DNA degradation were noted with the Qiagen method as
compared to the xylene-ethanol method when using the modified protocol with 1hour proteinase K digestion.
B. The Qiagen method also produced greater DNA yields quantified by Nanodrop
and Qubit. The modified protocol with 1-hour proteinase K Incubation
demonstrated the best DNA yields out of all the observed protocols.

The fourth comparison explored the two different deparaffinization
methods, using an overnight proteinase K digestion and with modifications to the
manufacturer-recommended QIAamp DNA FFPE Kit (“modified”) protocol (Figure
9). Again, the xylene-ethanol method demonstrated consistently higher
degradation and consistently lower DNA yields.
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A
B
A
Figure 9. Modified Protocol with Overnight Proteinase K Incubation
A. Lower levels of DNA degradation were noted with the Qiagen method as
compared to the xylene-ethanol method when using the modified protocol with
overnight proteinase k digestion.
B. The Qiagen method also produced greater DNA yield.

The fifth and final comparison explored the two different deparaffinization
methods, using a 90-minute proteinase K digestion and with modifications to the
manufacturer-recommended QIAamp DNA FFPE Kit (“modified”) protocol (Figure
10). Again, the Qiagen deparaffinization method demonstrated lower degradation
with higher DNA yields. However, the DNA yields in this experiment were lower
than in most other experiments.
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A

B

Figure 10. Modified Protocol with 90 Minute Proteinase K Incubation
A.ALower levels of DNA degradation were noted with the Qiagen method as
compared to the xylene-ethanol method when using the modified protocol with
90 minute proteinase K digestion.
B. The Qiagen method also produced greater DNA yield.

Overall, the method that appeared to produce the highest DNA yields with
the lowest amount of DNA degradation was the Qiagen deparaffinization method,
using a one-hour proteinase K digestion and with modifications to the
manufacturer-recommended QIAamp DNA FFPE Kit protocol.
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Discussion
Narrowing down an optimized protocol that effectively isolates DNA rom
FFPE samples is beneficial since this has been a challenge in the research
community. There were several considerations to account for when it came to
maintaining the integrity and the yields of the sample. After observing different
FFPE protocols incorporating modifications to the deparaffinization, proteinase K
incubation, and elution stages. It appears that the modified protocol with onehour proteinase K incubation using the Qiagen kit solution yielded the best
results for DNA preservation.
The previous thoughts were that the xylene-ethanol method with
modifications and an overnight incubation of proteinase K would work best for
producing the best DNA yields. However, it appears that the longer the
proteinase K incubation was, the lower the results for the DNA yield appeared. It
also seems that the increased cycles of xylene boosts the levels of degradation.
Although xylene-ethanol protocols have been frequently practiced, a more biofriendly solvent for deparaffinization may be preferred, like the Qiagen kit offers.
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Chapter 2. Mutational Analysis of ZFY in Sporadic Parathyroid Adenomas
Introduction
Recently, compelling genetic evidence was reported implicating the Zinc
Finger protein gene encoded by the X-chromosome (ZFX), a member of the
Kruppel C2H2 type zinc finger protein family, as a likely parathyroid adenoma
oncogene involved in almost 5% of cases (Soong, Arnold 2014). Recurrent
somatic mutations in ZFX were strikingly specific, focused on a hotspot of two
consecutive highly conserved arginine residues in the most C-terminal zinc finger
domain of the protein. ZFX is situated on the X-chromosome but escapes Xinactivation and is thus transcribed from both alleles in females. In males, the
highly homologous Zinc Finger protein gene encoded by the Y-chromosome
(ZFY) is expressed and provides dosage compensation. ZFX and ZFY are highly
homologous; in fact overall they are 92% identical, and while the zinc finger
domains are 97% identical. ZFY, like ZFX is a part of the Kruppel C2H2 type zinc
finger protein family. ZFY is a transcriptional activator that binds to the
consensus sequence 5'-AGGCCY-3'. There is very little known about ZFY,
however it is involved in multicellular organismal development, and has thirteen
zinc finger domains involved in nucleic acid binding (Lova-Solis 2014).
Since analogous mutations in ZFY could have similar tumorigenic effects
as those in ZFX, and with one such ZFY mutation already noted in a colon
carcinoma (COSMIC), we analyzed ZFY in a series of typical sporadic
parathyroid adenomas from male patients.
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Methods
Patients and Samples
Tumor

samples

parathyroidectomy

were

under

retrieved

the

from

circumstances

patients
of

that

received

managing

a

primary

hyperparathyroidism. Samples were collected from solely sporadic related cases.
This is based on negative family history related to primary hyperparathyroidism,
and multiple endocrine neoplasia. Every tumor sample had both the tumor and
matched germline control DNA for every designated patient. All samples were
obtained with informed consent in accordance with institutional review boardapproved protocols.
PCR and Sanger Sequencing
Primers were designed for ZFY’s seven coding exons (Table 3). Primers
were designed so that intron regions at the splice junctions were also examined
(Figure 11). The PCR reactions were carried out in 20 μL reaction volumes,
containing 25 ng of sample DNA, 12 μL of deionized H2O, 2 μL of 10X PCR
Buffer, 10 μM of dNTPs, 50 mM of MgCl2,, 1 μL of forward and reverse primer,
and 1 μL of Taq Gold (Applied Biosystems, Foster City, CA, USA). The thermal
cycles began with cycling conditions for exons 2-8. The PCR reactions were
performed by incubating at 95°C for 10 minutes, followed by 35 cycles of 95°C
for 30 seconds, 55°C for 30 seconds (60°C for exon7) and 72°C for one minute,
and a final elongation step of 72°C for 10 minutes.
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Table 3. ZFY Primer Design List
Exon

Forward

Reverse

1
2

AGAGAAAGGCCGTCCTGCAGC
CCCATGTATCCCTGGAAATC

CTTCGCGGACATTTACATAGC
CCCATGTATCCCTGGAAATC

Expected
Product Size
(BP)
360
446

3(pt.1)

GAGGAACACCAAGGACATAG

TTCTGGCATAGACATTGAGG

400

3(pt.2)

CAAGTGCTGGACTCAGATGT

TGTTAGAAAACACAGGTTTC

295

4

AACAAAGATGACATATGTCC

CATTTGGTTGAAACATTTGG

342

5
6
7
8(a)
8(b)
8(c)

ATACACTAAAACGTGTAAGC
CTGTGTGATCTCTGTAAACC
TGTCATTCATGAGTGTCAGG
ATTCATGAGGAGACCAGAAG
AAAAGGGGCCAACAAAATGC
CACATCAGTGTTTGCATTGC

TGATGGGTTGATAGGTGCAG
AGAAACCACTTTCAACAGTG
AATACATGTGGCCTACTAGC
GAGGTGGCGATTCAATAACC
TTCTGAAGGCCTGTGAAAGC
TCTGCTTCAAGGCCAACATC

278
297
441
493
454
431

8(d)

ACCTTCAGAAAAGAACCAGC

GGCCTGTGAAAGCCTTTCTCG

362

Figure 11. ZFY gene Primers
All the coding regions (exons 2-8) were PCR amplified. The 13 zinc fingers are
included in Exon 8.

The PCR products were purified with ExoSAP-IT (Affymetrix, Santa Clara,
CA) and were sequenced using standard Sanger sequencing methodology

24

(GeneWiz Inc., South Plainfield, NJ). Sequence data were analyzed using the
Sequencher DNA sequence analysis software to align multiple tumor sample
sequences along with reference sequences and to analyze possible variants in
the tumor and control samples. Potential mutations were confirmed by a second
cycle of sequencing from independent PCR reactions and by sequencing the
DNA from the blood sample, to check for germline variants.
Results
A total of 117 parathyroid adenomas were tested for sequence variants in
the coding region of ZFY. If the true frequency of ZFY mutation in parathyroid
adenoma was comparable to that of ZFX (6/130, 4.6%), this sample size of 117
was sufficiently powered to detect such mutations, with a statistical power of 80%
(Table 4).

Table 4. Statistical Power Calculation
Power Calculation

ZFX

ZFY

Sample Size

130

117

Average Value

6

5
(Expected Value)

Statistical Power

80%

Out of 117 cases, two variants were found (one still unconfirmed), each
represented in two different patients. The variants include one single nucleotide
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polymorphism and one point mutation. The single nucleotide polymorphism
(rs111915341) was found in the intron region preceding exon 5 (Figure 12).

Figure 12. ZFY Direct genomic DNA Sequencing of rs111915341
The single nucleotide polymorphism (rs111915341) was found in the intron
region preceding exon 5.

The novel variant, c.1402C>T, affects the first base of the codon,
resulting in histidine to tyrosine change at position 468 of the protein, affecting
the second zinc finger domain. Analysis of germline DNA suggested the variant
was somatic but neither finding has yet been replicated and must be considered
preliminary (Figure 13).
Two methods were used to determine any possible changes in
functionality due to the variant. The first tool used was a software program called
Polymorphism Phenotyping V2 (PolyPhen-2). With this tool, the histidine to
tyrosine change at position 468 is predicted to have a probably damaging effect,
with a score of 0.998 out of 1.0. This prediction was confirmed using a second
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software tool, PROVEAN, which also forecasts the impact of a variant on the
biological function of a protein. In this analysis, the default threshold is -2.5;
variants with a score equal to or below -2.5 are considered “deleterious”. Variants
with a score above -2.5 are considered “neutral”. The PROVEAN score for the
H468Y variant calculates it to be -3.068, suggesting it is deleterious.

Figure 13. ZFY Direct genomic DNA Sequencing of C1402 mutation.
A novel variant c.1402C>T was found in exon 8, the top chromatogram
demonstrates the normal sequence.

Discussion
Interest in sequencing ZFY came from the finding of recurrent, somatic
mutations of ZFX in parathyroid adenomas. While in ZFX, identified mutations
targeted a hotspot of two consecutive, highly conserved arginine residues at
positions 786 and 787 in the last zinc-finger domain. Sequencing the entire
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coding region was important to determine if there were any other mutations
outside of the hot spot region that could contribute to parathyroid tumorigenesis.
While no ZFY mutations had previously been identified in other endocrine
tumors, COSMIC notes a ZFY R782 mutation (corresponding to ZFX R787) in
colon cancer. With this knowledge in mind, ZFY was analyzed in a series of
typical, sporadic parathyroid adenomas from male patients.
One novel variant, c.1402C>T that remains to be replicated, was identified
in one tumor. The base change results in a histidine into tyrosine change at
position 468, altering it from basic to aromatic, yet still remaining polar. This is a
non-conservative mutation, which likely has deleterious effects. The variant is
found in the N terminal region where there are multiple C2H2 Zinc finger repeats.
This region has been shown to activate transcription when fused to a DNA
binding domain. This genetic alteration, if confirmed, would support the idea that
ZFY, like ZFX, may function as a direct-acting oncogene in the context of
parathyroid adenomas.
Surprisingly,

the

chromatogram

of

variant

c.1402C>T

appears

heterozygous, with two peaks representing the mutant thymine and the normal
cytosine. This is a noteworthy finding because typically only one peak for a male
patient would appear. The observed heterozygosity of the ZFY mutation may be
due to contamination with non-tumor cells, mosaicism, or tumor heterogeneity.
In mosaicism, subjects have an apparently heterozygous genotype due to
the presence of two different cell populations. Mosaicism is due to mitotic errors
during embryonic development. Mosaicism is rare, however there has been a
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study that provides evidence that mosaicism can account for some sporadic
cases of MEN1 (Klein R. 2004).
In tumor heterogeneity, clonal evolution results from distinct genetic
events that occur in the pathway from a normal cell into a tumor.

In this

transformation, a normal cell is hit randomly by a genetic event. This event
causes a genetic modification that leads to a clonal, subpopulation of cells.
These cells, unlike the normal cells, multiply more and die less often. Those
same cells may be hit again and begin to further expand because they have a
growth advantage over the previous cells.
The entire coding region of ZFY was fully sequenced in 117 of these
tumors, with one preliminary variant found with confirmation pending. The highest
priority in future observations will incorporate replicating this variant to confirm
this mutation. This study suggests experimental evidence for the new role of
mutant ZFY as a possible parathyroid oncogene. It will also provide a framework
for our subsequent studies to address the binding sites and target gene
promoters crucial to ZFY’s oncogenic functions. Further, these studies of the
mechanisms behind parathyroid adenoma development will help address crucial
and more general questions on how benign and malignant growths differ and
how that information might help in preventing human malignancies in multiple
tissue contexts.
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Chapter 3: CDKI Mutational Analysis
Introduction
The cyclin dependent kinase inhibitors (CDKIs) function as negative
regulators of cell cycle progression. CDKIs are categorized into either the Cip/Kip
or INK4 family. The cyclins that are a part of the Cip/Kip family include p21
(encoded by CDKN1A), p27 (CDKN1B), and p57 (CDKN1C). The Cip/Kip family
is well characterized for their role as negative regulators of G1 phase cell cycle
progression by inhibiting a broad spectrum of cyclin-CDK complexes (Sherr and
Roberts 1999). The INK4 family members include p16 and p14, (ARF encoding,
CDKN2A/ARF), p15 (CDKN2B), p18 (CDKN2C), and p19 (CDKN2D). The INK4
family inhibits the activity of CDK6 and CDK4 complexes.
A germline mutation identified in CDKN1B, encoding p27, established the
involvement of CDKI gene mutations in a MEN 1-like syndrome (Pellegata et al.,
2006). This discovery was later confirmed by other investigators (Malatore S., et.
al. 2010, Martucci F, 2012), and led to the identification of variants in other
CDKIs (Costa-Guda J., 2013). There are no established genotype-phenotype
correlations between patients presenting with MEN1 syndrome due to mutations
in the MEN1 gene or in the CDKI genes. For this reason, it is especially important
to determine the underlying genetic cause in each patient who presents clinically
with MEN1 syndrome features, so that potential genotype-phenotype correlations
can be made, which may ultimately help guide treatment decisions.
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Methods
One female patient with a diagnosis of phenotypic MEN1, based on a
personal history of prolactinoma and familial hyperparathyroidism, but a normal
MEN1 gene status was examined in this study. We received germline DNA and
performed PCR and Sanger sequence analysis of four CDKI genes (CDKN2B,
CDKN2C, CDKN1A, or CDKN1B), as previously described (Costa-Guda J., et. al
2011, 2013).
Results
The four CDKI genes were analyzed and one sequence variant was
identified. This novel c.34G>A variant was found in exon 2 of the CDKN2C gene.
This heterozygous, missense mutation changes the first base of the codon,
resulting in an amino acid change at position 12 from an alanine to threonine
(Figure 14).
Two methods were used to predict the functional effects of the CDKN2C
variant. The polymorphism phenotyping V2 (Polyphen-2) software program was
used for predicting the impact of an amino acid substitution on the structure and
function of a human protein using physical and comparative considerations. The
PolyPhen-2 score ranges from 0.0 (tolerated) to 1.0 (deleterious). Variants with
scores of 0.0 are predicted to be benign. Values closer to 1.0 are more
confidently predicted to be deleterious. The mutation was predicted to be
probably damaging with a score of 0.983 out of 1.0.
Prediction was verified using PROVEAN. PROVEAN scores equal to or
below a predefined threshold (e.g. -2.5) are predicted to have a "deleterious"
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effect, while scores above the threshold predict a "neutral" effect. The PROVEAN
score for the identified mutation was -3.626, suggesting it as deleterious.

Figure 14. CDKN2C gene Germline variant c.34G>A
These chromatograms show a novel c.34G>A variant for the germline sequence.
A mutation in the CDKNC gene was found at position 34, encoding a codon at
amino acid position 12. This alters the codon from an alanine (GCA) to threonine
(ACA) residue also, displaying heterozygosity [guanine/adenine].

Discussion
In this study several cyclin dependent kinase inhibitors were analyzed in a
patient with phenotypic MEN1 but normal MEN1 gene status. A novel variant
c.34G>A, in CDKN2C, resulting in a p.A12T change in p18 protein, was found.
The protein variant is predicted to have a "deleterious" effect by the software
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program PROVEAN and polyphen-2. As expected for a germline mutation, this
variant was heterozygous. This specific variant was not found in National Center
of Biotechnology Information (NCBI), Catalogue of Somatic Mutations in Cancer
(COSMIC), or in the single nucleotide polymorphism database (dbSNP).
The evidence, pending confirmation, of the variant c.34G>A in CDKN2C
contributing to the clinical phenotype of MEN1 syndrome would be strengthened
by directly determining an abnormal impact of the mutation on CDKN2C activity.
The significance of this finding can be verified through experiments that
demonstrate a relationship between the genotype with the variant and the clinical
phenotype by incorporating a cellular or animal model (Cassanova et al., 2014).
Further studies, in which other affected and unaffected family members
are examined is another way to strengthen the evidence of the CDKN2C
mutation’s relevance. Concordance of the candidate genotype and clinical
phenotype in family members of the patient would help demonstrate the
relevance of the CDKN2C variant. However, the inability to identify this variant in
family members with the same clinical manifestations would negate its
significance (Cassanova et al., 2014).
The germline DNA of a single patient was sequenced in order to identify
any mutations in the CDKIs that could contribute to the molecular pathogenesis
of this patient’s adenomas, linked to MEN1 syndrome. The Identification of a
missense mutation in the CDKN2C gene could potentially suggest that it plays a
role in the phenotypic presentation of the MEN1 syndrome. Further knowledge
on this inherited mutation might be useful in the management of disease by
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providing guidance for best course of action for treatment for others in the same
family. The patients could benefit from a positive or negative status report. For
instance, a positive status could direct them to the best monitoring and treatment
options. On the other hand, individuals with a negative status will be spared from
unnecessary screenings and checkups. In general, an increased patient sample
pool together, with powerful tools like Next Generation Sequencing technology,
will assist in the discovery of more variants associated with parathyroid related
diseases.
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List of Abbreviations
CASR

Calcium Sensing Receptor

CCND1

Human Cyclin D1 proto-oncogene

CDK

Cyclin dependent kinase

CDKI

Cyclin dependent kinase inhibitor

CDKN1A

Human cyclin dependent kinase inhibitor 1A gene, p21

CDKN2A

Human cyclin dependent kinase inhibitor 1A gene, p16

CDKN1B

Human cyclin dependent kinase inhibitor 1B gene, p27

CDKN2B

Human cyclin dependent kinase inhibitor 2B gene, p15

CDKN1C

Human cyclin dependent kinase inhibitor 1C gene, p57

CDKN2C

Human cyclin dependent kinase inhibitor 2C gene, p18

CDKN2D

Human cyclin dependent kinase inhibitor 2D gene, p19

CTNNB1

Human catenin (cadherin-associated protein), beta 1 gene

DNA

Deoxyribonucleic acid

FHH

Familial hypocalciuric hypercalcemia

HPT-JT

Hyperparathyroidism-jaw tumor syndrome

HRPT2

Human Hyperparathyroidism 2 gene, encoding parafibromin

(CDC73)
MEN1

Multiple endocrine neoplasia type 1

MEN1

Human multiple endocrine neoplasia type 1 gene

MEN2

Multiple endocrine neoplasia type 2

MEN2A

Multiple endocrine neoplasia type 2A

MEN2B

Multiple endocrine neoplasia type 2B
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MTC

Medullary thyroid cancer

PCR

Polymerase chain reaction

PTH

Parathyroid hormone

RET

Human RET (rearranged during transfection) proto-oncogene

SNP

Single nucleotide polymorphism
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